Husseini, Jad SJad SHusseiniAmorim, Bárbara JuarezBárbara JuarezAmorimTorrado-Carvajal, AngelAngelTorrado-CarvajalPrabhu, VinayVinayPrabhuGroshar, DavidDavidGrosharUmutlu, LaleLaleUmutluHerrmann, KenKenHerrmannCañamaque, Lina GarcíaLina GarcíaCañamaqueGarzón, José Ramón GarcíaJosé Ramón GarcíaGarzónPalmer, William EWilliam EPalmerHeidari, PedramPedramHeidariTIFFANY TING-FANG SHIHSosna, JacobJacobSosnaMatushita, CristinaCristinaMatushitaCerci, JulianoJulianoCerciQueiroz, MarceloMarceloQueirozMuglia, Valdair FranciscoValdair FranciscoMugliaNogueira-Barbosa, Marcello HMarcello HNogueira-BarbosaBorra, Ronald J HRonald J HBorraKwee, Thomas CThomas CKweeGlaudemans, Andor W J MAndor W J MGlaudemansEvangelista, LauraLauraEvangelistaSalvatore, MarcoMarcoSalvatoreCuocolo, AlbertoAlbertoCuocoloSoricelli, AndreaAndreaSoricelliHerold, ChristianChristianHeroldLaghi, AndreaAndreaLaghiMayerhoefer, MariusMariusMayerhoeferMahmood, UmarUmarMahmoodCatana, CiprianCiprianCatanaDaldrup-Link, Heike EHeike EDaldrup-LinkRosen, BruceBruceRosenCatalano, Onofrio AOnofrio ACatalano2021-03-222021-03-222021-02-2216197070https://scholars.lib.ntu.edu.tw/handle/123456789/554368MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use.animationMR; Metastases; Osseous; PET; PET/MR; PET/MRI; Skeletal[SDGs]SDG3dotanoc ga 68; edotreotide ga 68; fluciclovine f 18; fluorodeoxyglucose f 18; gallium dotatate ga 68; prostate specific membrane antigen f 18; prostate specific membrane antigen ga 68; sodium fluoride f 18; tracer; unclassified drug; radiopharmaceutical agent; adult; Article; bone metastasis; breast cancer; cancer diagnosis; cancer staging; consensus; diagnostic value; human; lung cancer; lymphoma; neuroendocrine tumor; nuclear magnetic resonance imaging; positron emission tomography; positron emission tomography-computed tomography; primary tumor; prostate adenocarcinoma; radiation dose; well differentiated neuroendocrine tumor; expert witness; nuclear magnetic resonance imaging; positron emission tomography; positron emission tomography-computed tomography; Expert Testimony; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticalsjournal article10.1007/s00259-021-05198-2336195992-s2.0-85101198246https://api.elsevier.com/content/abstract/scopus_id/85101198246